Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» amivantamab
amivantamab
JNJ's amivantamab puts more data behind the hype
JNJ's amivantamab puts more data behind the hype
EP Vantage
JNJ
amivantamab
exon 20-insertion NSCLC
Flag link:
J&J pushes new amivantamab data for NSCLC subset, trying to bolster case for quick FDA approval
J&J pushes new amivantamab data for NSCLC subset, trying to bolster case for quick FDA approval
Endpoints
JNJ
amivantamab
non-small cell lung cancer
Flag link:
Best-selling Tagrisso further outpaces an upcoming J&J rival, winning approval in new NSCLC indication
Best-selling Tagrisso further outpaces an upcoming J&J rival, winning approval in new NSCLC indication
Endpoints
AstraZeneca
Tagrisso
non-small cell lung cancer
JNJ
amivantamab
Flag link:
In a first, Janssen submits lung cancer bispecific hopeful amivantamab to the FDA
In a first, Janssen submits lung cancer bispecific hopeful amivantamab to the FDA
Fierce Biotech
Janssen
non-small cell lung cancer
FDA
amivantamab
JNJ
metastatic non-small cell lung cancer
Flag link:
